- Home
- SUPV vs ATXS Comparison
SUPV vs ATXS Comparison
Compare SUPV & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPV
- ATXS
- Stock Information
- Founded
- SUPV 1887
- ATXS 2008
- Country
- SUPV Argentina
- ATXS United States
- Employees
- SUPV N/A
- ATXS N/A
- Industry
- SUPV Commercial Banks
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- SUPV Finance
- ATXS Health Care
- Exchange
- SUPV Nasdaq
- ATXS Nasdaq
- Market Cap
- SUPV 713.3M
- ATXS 628.6M
- IPO Year
- SUPV 2016
- ATXS 2015
- Fundamental
- Price
- SUPV $7.33
- ATXS $11.87
- Analyst Decision
- SUPV
- ATXS Strong Buy
- Analyst Count
- SUPV 0
- ATXS 5
- Target Price
- SUPV N/A
- ATXS $25.20
- AVG Volume (30 Days)
- SUPV 1.1M
- ATXS 463.9K
- Earning Date
- SUPV 11-25-2024
- ATXS 11-11-2024
- Dividend Yield
- SUPV 2.33%
- ATXS N/A
- EPS Growth
- SUPV 514.29
- ATXS N/A
- EPS
- SUPV 0.24
- ATXS N/A
- Revenue
- SUPV $582,756,903.00
- ATXS N/A
- Revenue This Year
- SUPV N/A
- ATXS N/A
- Revenue Next Year
- SUPV N/A
- ATXS N/A
- P/E Ratio
- SUPV $7.68
- ATXS N/A
- Revenue Growth
- SUPV N/A
- ATXS N/A
- 52 Week Low
- SUPV $1.76
- ATXS $4.26
- 52 Week High
- SUPV $8.74
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- SUPV 45.51
- ATXS 54.19
- Support Level
- SUPV $6.90
- ATXS $10.62
- Resistance Level
- SUPV $8.60
- ATXS $11.85
- Average True Range (ATR)
- SUPV 0.32
- ATXS 0.79
- MACD
- SUPV -0.13
- ATXS -0.02
- Stochastic Oscillator
- SUPV 25.29
- ATXS 58.66
About SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, Asset Management, and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.